Literature DB >> 20937594

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.

Manu Lopus1, Emin Oroudjev, Leslie Wilson, Sharon Wilhelm, Wayne Widdison, Ravi Chari, Mary Ann Jordan.   

Abstract

Maytansine is a potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations. However, its side effects and lack of tumor specificity have prevented successful clinical use. Recently, antibody-conjugated maytansine derivatives have been developed to overcome these drawbacks. Several conjugates show promising early clinical results. We evaluated the effects on microtubule polymerization and dynamic instability of maytansine and two cellular metabolites (S-methyl-DM1 and S-methyl-DM4) of antibody-maytansinoid conjugates that are potent in cells at picomolar levels and that are active in tumor-bearing mice. Although S-methyl-DM1 and S-methyl-DM4 inhibited polymerization more weakly than maytansine, at 100 nmol/L they suppressed dynamic instability more strongly than maytansine (by 84% and 73%, respectively, compared with 45% for maytansine). However, unlike maytansine, S-methyl-DM1 and S-methyl-DM4 induced tubulin aggregates detectable by electron microscopy at concentrations ≥2 μmol/L, with S-methyl-DM4 showing more extensive aggregate formation than S-methyl-DM1. Both maytansine and S-methyl-DM1 bound to tubulin with similar K(D) values (0.86 ± 0.2 and 0.93 ± 0.2 μmol/L, respectively). Tritiated S-methyl-DM1 bound to 37 high-affinity sites per microtubule (K(D), 0.1 ± 0.05 μmol/L). Thus, S-methyl-DM1 binds to high-affinity sites on microtubules 20-fold more strongly than vinblastine. The high-affinity binding is likely at microtubule ends and is responsible for suppression of microtubule dynamic instability. Also, at higher concentrations, S-methyl-DM1 showed low-affinity binding either to a larger number of sites on microtubules or to sedimentable tubulin aggregates. Overall, the maytansine derivatives that result from cellular metabolism of the antibody conjugates are themselves potent microtubule poisons, interacting with microtubules as effectively as or more effectively than the parent molecule.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937594      PMCID: PMC2954514          DOI: 10.1158/1535-7163.MCT-10-0644

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  35 in total

1.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

2.  The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides.

Authors:  S M Kupchan; Y Komoda; A R Branfman; A T Sneden; W A Court; G J Thomas; H P Hintz; R M Smith; A Karim; G A Howie; A K Verma; Y Nagao; R G Dailey; V A Zimmerly; W C Sumner
Journal:  J Org Chem       Date:  1977-07-08       Impact factor: 4.354

3.  Binding of maytansine to rat brain tubulin.

Authors:  F Mandelbaum-Shavit; M K Wolpert-DeFilippes; D G Johns
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus.

Authors:  S M Kupchan; Y Komoda; W A Court; G J Thomas; R M Smith; A Karim; C J Gilmore; R C Haltiwanger; R F Bryan
Journal:  J Am Chem Soc       Date:  1972-02-23       Impact factor: 15.419

6.  Maytansine binding to the vinblastine sites of tubulin.

Authors:  B Bhattacharyya; J Wolff
Journal:  FEBS Lett       Date:  1977-03-15       Impact factor: 4.124

7.  Binding of maytansinoids to tubulin.

Authors:  J York; M K Wolpert-DeFilippes; D G Johns; V S Sethi
Journal:  Biochem Pharmacol       Date:  1981-12-01       Impact factor: 5.858

8.  Interaction of vinblastine with steady-state microtubules in vitro.

Authors:  L Wilson; M A Jordan; A Morse; R L Margolis
Journal:  J Mol Biol       Date:  1982-07-25       Impact factor: 5.469

9.  Effects of inhibitors of tubulin polymerization on GTP hydrolysis.

Authors:  C M Lin; E Hamel
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

10.  Tubulin-colchicine complexes differentially poison opposite microtubule ends.

Authors:  K W Farrell; L Wilson
Journal:  Biochemistry       Date:  1984-07-31       Impact factor: 3.162

View more
  59 in total

1.  A molecular and structural mechanism for G protein-mediated microtubule destabilization.

Authors:  Rahul H Davé; Witchuda Saengsawang; Manu Lopus; Sonya Davé; Leslie Wilson; Mark M Rasenick
Journal:  J Biol Chem       Date:  2010-11-26       Impact factor: 5.157

2.  Modeling the effects of drug binding on the dynamic instability of microtubules.

Authors:  Peter Hinow; Vahid Rezania; Manu Lopus; Mary Ann Jordan; Jack A Tuszyński
Journal:  Phys Biol       Date:  2011-08-12       Impact factor: 2.583

Review 3.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

4.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

Review 5.  Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.

Authors:  Shi Xu
Journal:  Pharm Res       Date:  2015-06-25       Impact factor: 4.200

6.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

Review 7.  Protein based therapeutic delivery agents: Contemporary developments and challenges.

Authors:  Liming Yin; Carlo Yuvienco; Jin Kim Montclare
Journal:  Biomaterials       Date:  2017-04-21       Impact factor: 12.479

Review 8.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

9.  The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Authors:  Hernan Carol; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

10.  Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Authors:  Maureen C Ryan; Maria Corinna Palanca-Wessels; Brian Schimpf; Kristine A Gordon; Heather Kostner; Brad Meyer; Changpu Yu; Heather A Van Epps; Dennis Benjamin
Journal:  Blood       Date:  2017-09-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.